Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulforafan alfadex - Evgen

Drug Profile

Sulforafan alfadex - Evgen

Alternative Names: SFX-01; Stabilised sulforaphane; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 10 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lalilab
  • Developer Evgen Pharma
  • Class Antihaemorrhagics; Antineoplastics; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Preclinical Multiple sclerosis
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia

Most Recent Events

  • 05 Sep 2019 Evgen and Guy's and St Thomas' enter into a Memorandum of Understanding for clinical trials of SFX 01 in Autism Spectrum Disorder
  • 05 Sep 2019 Evgen and Guy's and St Thomas' plans a phase II trial for Pervasive child development disorders
  • 01 Mar 2019 Evgen Pharma completes the phase II STEM trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, United Kingdom, Spain, France (PO) (NCT02970682)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top